oab approv race realli begin
morn good morn axon
fda approv urinari indic last reiter overw eight rate price target
last night axon r-snm receiv fda approv expand indic urinari indic overact bladder urinari
retent indic market eagerli patient ait believ axon ell posit
gain signific share sacral neuromodul market
septemb axon r-snm sacral neuromodul system receiv fda approv indic fecal incontin origin
system expect approv ith urinari indic larger tradit indic due
time file fecal indic came first
recent expect approv time urinari indic approv octob novemb
axon readi go ith commerci team includ territori manag clinic support specialist sale manag
fact axon alreadi start ship commerci implant alreadi start first implant ith urinari
indic demand unleash institut physician ere ait oab indic move
ahead place orders/impl
revenu project follow sacral neuromodul market market control axon entri
 ith axon entri market advanc next gener forw ard develop plan launch
product sometim spring
ever convers ith physician indic axon could still captur signific market share forecast assum
share captur ramp ever physician symposium attend albeit bias sampl suggest far
higher share ith mani physician indic readi set go oab day physician seminar takeaw ay reit ow
axon ill host earn call even et ebcast avail http //ir axonicsmodul com/events-
inform see initi report address innov void initi ith overw eight rate
 oo stew bloomberg im email call kristen
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu axn ev/sal basi price target appli multipl sale estim
million hich compar smid cap high grow th med-tech compani
risk may imped achiev barclay research valuat price risk includ time fda
approv adopt clinician abil penetr market competit product launch particularli interstim
micro fda manufactur issu recal also risk factor reimburs chang
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim discount med-tech compani
trade hich believ appropri given slow er grow th profil sinc trade averag discount
 ever past year compani improv grow th profil durabl mid-singl
digit grow th hich believ arrant premium current trade calendar ep estim
thu expect pe multipl hold
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform hich expect regulatori approv outsid unit
state begin key product includ micra av interstim micro minim futur iter continu blood
glucos monitor devic transcathet valv system upsid greater success ith new product margin expans
risk includ signific reimburs chang competit pressur product failur fda govern
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
fd barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
